An anti-B cell maturation antigen bispecific antibody for multiple myeloma.

@article{Ramadoss2015AnAC,
  title={An anti-B cell maturation antigen bispecific antibody for multiple myeloma.},
  author={N. Ramadoss and Andrew D Schulman and S. Choi and D. Rodgers and Stephanie A. Kazane and Chan Hyuk Kim and B. Lawson and T. Young},
  journal={Journal of the American Chemical Society},
  year={2015},
  volume={137 16},
  pages={
          5288-91
        }
}
The development of immunotherapies for multiple myeloma is critical to provide new treatment strategies to combat drug resistance. We report a bispecific antibody against B cell maturation antigen (BiFab-BCMA), which potently and specifically redirects T cells to lyse malignant multiple myeloma cells. BiFab-BCMA lysed target BCMA-positive cell lines up to 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed in an analogous fashion. Further, BiFab-BCMA robustly… Expand
Targeting B-cell maturation antigen in multiple myeloma.
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation
  • T. Bera
  • Chemistry, Medicine
  • Biomolecules
  • 2020
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Antibody targeting of B-cell maturation antigen on malignant plasma cells
CD38 as a Therapeutic Target
Chimeric antigen receptor therapy for cancer.
...
1
2
3
...